ORIC Pharmaceuticals (ORIC) Competitors $9.39 -0.36 (-3.69%) Closing price 06/11/2025 04:00 PM EasternExtended Trading$9.06 -0.33 (-3.47%) As of 06/11/2025 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock ORIC vs. APLS, OGN, HCM, IBRX, AMRX, XENE, MIRM, ARWR, AAPG, and NAMSShould you be buying ORIC Pharmaceuticals stock or one of its competitors? The main competitors of ORIC Pharmaceuticals include Apellis Pharmaceuticals (APLS), Organon & Co. (OGN), HUTCHMED (HCM), ImmunityBio (IBRX), Amneal Pharmaceuticals (AMRX), Xenon Pharmaceuticals (XENE), Mirum Pharmaceuticals (MIRM), Arrowhead Pharmaceuticals (ARWR), Ascentage Pharma Group International (AAPG), and NewAmsterdam Pharma (NAMS). These companies are all part of the "pharmaceutical products" industry. ORIC Pharmaceuticals vs. Its Competitors Apellis Pharmaceuticals Organon & Co. HUTCHMED ImmunityBio Amneal Pharmaceuticals Xenon Pharmaceuticals Mirum Pharmaceuticals Arrowhead Pharmaceuticals Ascentage Pharma Group International NewAmsterdam Pharma ORIC Pharmaceuticals (NASDAQ:ORIC) and Apellis Pharmaceuticals (NASDAQ:APLS) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, media sentiment, institutional ownership, risk, valuation, dividends, community ranking and profitability. Do institutionals and insiders believe in ORIC or APLS? 95.1% of ORIC Pharmaceuticals shares are held by institutional investors. Comparatively, 96.3% of Apellis Pharmaceuticals shares are held by institutional investors. 6.8% of ORIC Pharmaceuticals shares are held by company insiders. Comparatively, 6.5% of Apellis Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. Do analysts rate ORIC or APLS? ORIC Pharmaceuticals presently has a consensus target price of $19.17, suggesting a potential upside of 103.86%. Apellis Pharmaceuticals has a consensus target price of $40.05, suggesting a potential upside of 107.69%. Given Apellis Pharmaceuticals' higher possible upside, analysts clearly believe Apellis Pharmaceuticals is more favorable than ORIC Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ORIC Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 3.00Apellis Pharmaceuticals 0 Sell rating(s) 9 Hold rating(s) 11 Buy rating(s) 1 Strong Buy rating(s) 2.62 Does the MarketBeat Community believe in ORIC or APLS? Apellis Pharmaceuticals received 276 more outperform votes than ORIC Pharmaceuticals when rated by MarketBeat users. However, 76.00% of users gave ORIC Pharmaceuticals an outperform vote while only 66.29% of users gave Apellis Pharmaceuticals an outperform vote. CompanyUnderperformOutperformORIC PharmaceuticalsOutperform Votes7676.00% Underperform Votes2424.00% Apellis PharmaceuticalsOutperform Votes35266.29% Underperform Votes17933.71% Is ORIC or APLS more profitable? ORIC Pharmaceuticals has a net margin of 0.00% compared to Apellis Pharmaceuticals' net margin of -34.97%. ORIC Pharmaceuticals' return on equity of -44.54% beat Apellis Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets ORIC PharmaceuticalsN/A -44.54% -40.72% Apellis Pharmaceuticals -34.97%-103.11%-28.96% Which has more volatility and risk, ORIC or APLS? ORIC Pharmaceuticals has a beta of 1.49, meaning that its share price is 49% more volatile than the S&P 500. Comparatively, Apellis Pharmaceuticals has a beta of 0.68, meaning that its share price is 32% less volatile than the S&P 500. Does the media favor ORIC or APLS? In the previous week, ORIC Pharmaceuticals had 3 more articles in the media than Apellis Pharmaceuticals. MarketBeat recorded 13 mentions for ORIC Pharmaceuticals and 10 mentions for Apellis Pharmaceuticals. Apellis Pharmaceuticals' average media sentiment score of 0.98 beat ORIC Pharmaceuticals' score of 0.90 indicating that Apellis Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ORIC Pharmaceuticals 7 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Apellis Pharmaceuticals 5 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has higher valuation & earnings, ORIC or APLS? ORIC Pharmaceuticals has higher earnings, but lower revenue than Apellis Pharmaceuticals. Apellis Pharmaceuticals is trading at a lower price-to-earnings ratio than ORIC Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioORIC PharmaceuticalsN/AN/A-$100.70M-$1.87-5.03Apellis Pharmaceuticals$775.84M3.12-$528.63M-$1.79-10.77 SummaryORIC Pharmaceuticals and Apellis Pharmaceuticals tied by winning 9 of the 18 factors compared between the two stocks. Get ORIC Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ORIC and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ORIC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ORIC vs. The Competition Export to ExcelMetricORIC PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$669.58M$6.86B$5.58B$8.61BDividend YieldN/A2.49%5.27%4.19%P/E Ratio-5.188.8427.2920.07Price / SalesN/A257.85410.86158.91Price / CashN/A65.8538.2534.64Price / Book2.756.597.124.71Net Income-$100.70M$143.71M$3.23B$247.80M7 Day Performance3.55%4.13%2.99%2.30%1 Month Performance85.08%14.38%12.39%9.55%1 Year Performance17.38%5.31%31.73%14.92% ORIC Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ORICORIC Pharmaceuticals3.9106 of 5 stars$9.39-3.7%$19.17+104.1%+17.2%$667.52MN/A-5.1680News CoverageAnalyst RevisionAPLSApellis Pharmaceuticals4.7118 of 5 stars$19.14+13.1%$40.05+109.3%-54.9%$2.41B$775.84M-9.43770Analyst RevisionHigh Trading VolumeOGNOrganon & Co.4.7934 of 5 stars$9.22-0.1%$18.00+95.3%-50.1%$2.40B$6.29B2.7710,000Trending NewsHCMHUTCHMED1.3586 of 5 stars$13.60-2.1%$19.00+39.7%-4.2%$2.37B$630.20M0.001,760Upcoming EarningsIBRXImmunityBio2.3442 of 5 stars$2.67+0.4%$12.25+358.8%-45.6%$2.36B$31.22M-2.90590High Trading VolumeAMRXAmneal Pharmaceuticals3.7149 of 5 stars$7.42+1.4%$11.50+55.0%+10.7%$2.33B$2.83B-10.917,600Positive NewsXENEXenon Pharmaceuticals3.5091 of 5 stars$30.07+4.2%$54.82+82.3%-15.0%$2.31B$7.50M-10.66210Options VolumeAnalyst RevisionMIRMMirum Pharmaceuticals3.8483 of 5 stars$45.97+3.4%$60.73+32.1%+85.0%$2.28B$379.25M-22.76140Analyst RevisionARWRArrowhead Pharmaceuticals3.5429 of 5 stars$16.40+2.1%$42.13+156.9%-32.1%$2.26B$545.21M-3.17400Analyst RevisionAAPGAscentage Pharma Group InternationalN/A$25.22+3.4%N/AN/A$2.20B$980.65M0.00600NAMSNewAmsterdam Pharma2.9856 of 5 stars$18.93+4.5%$43.00+127.2%+3.2%$2.13B$47.14M-10.074Trending NewsAnalyst ForecastAnalyst Revision Related Companies and Tools Related Companies Apellis Pharmaceuticals Competitors Organon & Co. Competitors HUTCHMED Competitors ImmunityBio Competitors Amneal Pharmaceuticals Competitors Xenon Pharmaceuticals Competitors Mirum Pharmaceuticals Competitors Arrowhead Pharmaceuticals Competitors Ascentage Pharma Group International Competitors NewAmsterdam Pharma Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ORIC) was last updated on 6/12/2025 by MarketBeat.com Staff From Our PartnersTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredBillionaires are piling into this gold investmentBillionaires Are Piling into a Special Gold Investment With record gold prices, everyday Americans are scra...Weiss Ratings | SponsoredBig Changes Coming to Social Security?According to legendary investor Louis Navellier... This new Trump move could soon not only save Social Secu...InvestorPlace | SponsoredSHOCKING: Musk's Pentagon Secret Mission...It's about a harrowing message discovered on December 16, 2024: "美国军方暗杀名单" It's the reason President Tru...Behind the Markets | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ORIC Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ORIC Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy ORIC Stock Free ORIC Stock Alerts